期刊
CA-A CANCER JOURNAL FOR CLINICIANS
卷 62, 期 5, 页码 299-308出版社
WILEY
DOI: 10.3322/caac.21141
关键词
-
类别
资金
- Prostate Cancer Foundation Young Investigator Award
- Dendreon Corporation
- Bristol-Myers Squibb
- Novartis
- Celgene Corporation
There have been more drugs approved by the US Food and Drug Administration for the treatment of castration-resistant prostate cancer in the past 3 years than in the prior 3 decades, with additional drugs on the verge of approval based on the results of recently reported randomized trials. While an improvement in the understanding of the pathogenesis of castration-resistant prostate cancer has undeniably accelerated the transition of novel approaches from bench to bedside, the recent successes in the treatment of prostate cancer are also a result of the efforts of clinical investigators to redefine the framework in which drugs for castration-resistant disease are evaluated. This review will explore the shifting paradigm in drug development for castration-resistant prostate cancer over the past several decades, and highlight how new definitions, trial designs, and endpoints have facilitated the emergence of new therapies for this challenging disease. CA Cancer J Clin 2012;. (c) 2012 American Cancer Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据